WO2005107717A3 - Oral dosage form for the extended release of biguanide and sulfonylurea - Google Patents

Oral dosage form for the extended release of biguanide and sulfonylurea Download PDF

Info

Publication number
WO2005107717A3
WO2005107717A3 PCT/IB2005/001281 IB2005001281W WO2005107717A3 WO 2005107717 A3 WO2005107717 A3 WO 2005107717A3 IB 2005001281 W IB2005001281 W IB 2005001281W WO 2005107717 A3 WO2005107717 A3 WO 2005107717A3
Authority
WO
WIPO (PCT)
Prior art keywords
biguanide
sulfonylurea
dosage form
extended release
oral dosage
Prior art date
Application number
PCT/IB2005/001281
Other languages
French (fr)
Other versions
WO2005107717A8 (en
WO2005107717A2 (en
Inventor
Amit Kumar Kesarwani
Manish Chawla
Rajeev Singh Raghuvanshi
Ashok Rampal
Original Assignee
Ranbaxy Lab Ltd
Kersarwani Amit Kumar
Manish Chawla
Rajeev Singh Raghuvanshi
Ashok Rampal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd, Kersarwani Amit Kumar, Manish Chawla, Rajeev Singh Raghuvanshi, Ashok Rampal filed Critical Ranbaxy Lab Ltd
Publication of WO2005107717A2 publication Critical patent/WO2005107717A2/en
Publication of WO2005107717A8 publication Critical patent/WO2005107717A8/en
Publication of WO2005107717A3 publication Critical patent/WO2005107717A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a solid dosage form comprising a combination of a biguanide and a sulfonylurea. The dosage form provides an extended-release phase of a biguanide and an extended release phase of a sulfonylurea. Also provided are processes for the preparation thereof.
PCT/IB2005/001281 2004-05-11 2005-05-11 Oral dosage form for the extended release of biguanide and sulfonylurea WO2005107717A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN860/DEL/2004 2004-05-11
IN860DE2004 2004-05-11

Publications (3)

Publication Number Publication Date
WO2005107717A2 WO2005107717A2 (en) 2005-11-17
WO2005107717A8 WO2005107717A8 (en) 2006-03-02
WO2005107717A3 true WO2005107717A3 (en) 2006-05-18

Family

ID=34967067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001281 WO2005107717A2 (en) 2004-05-11 2005-05-11 Oral dosage form for the extended release of biguanide and sulfonylurea

Country Status (1)

Country Link
WO (1) WO2005107717A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077494A2 (en) * 2005-01-24 2006-07-27 Ranbaxy Laboratories Limited A process for preparing solid dosage forms for extended-release of biguanide and sulfonylurea
WO2006092711A2 (en) * 2005-03-02 2006-09-08 Ranbaxy Laboratories Limited Extended release tablets of metformin and glipizide
WO2006123213A1 (en) * 2005-05-18 2006-11-23 Ranbaxy Laboratories Limited Modified release formulations of gliclazide
EP2228066A1 (en) * 2009-03-03 2010-09-15 LEK Pharmaceuticals d.d. Pharmaceutical compositions of sulphonylurea-based active pharmaceutical ingredient with excellent dissolution properties
CN104177302B (en) * 2014-07-30 2016-02-03 沈阳药科大学 Glipizide derivative and its preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018932A1 (en) * 1997-10-15 1999-04-22 Edward Mendell Co., Inc. Novel once-a-day controlled release sulfonylurea formulation
WO2000040233A1 (en) * 1998-12-30 2000-07-13 Hexal Ag Pharmaceutical composition containing metformin, acarbose or glimepiride and optionally poly-(dimethyl)-siloxane
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018932A1 (en) * 1997-10-15 1999-04-22 Edward Mendell Co., Inc. Novel once-a-day controlled release sulfonylurea formulation
WO2000040233A1 (en) * 1998-12-30 2000-07-13 Hexal Ag Pharmaceutical composition containing metformin, acarbose or glimepiride and optionally poly-(dimethyl)-siloxane
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes

Also Published As

Publication number Publication date
WO2005107717A8 (en) 2006-03-02
WO2005107717A2 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
IL246171B (en) Processes for the preparation of peptide-based compounds
ZA200704661B (en) Solid, orally appliance pharmaceutical administration forms containing rivaroxaban having modified release
IL177283A (en) Pyrazolopyrimidine compounds, use thereof for the preparation of medicaments and pharmaceutical compositions comprising same
WO2007146248A3 (en) Stable laquinimod preparations
WO2006024479A3 (en) Pharmaceutical multiparticulate compositions comprising mycophenolic acid or mycophenolate sodium and combination compositions with rapamycin
HUE037069T2 (en) Process for the preparation of highly pure 2,4'-methylenediphenyldiisocyanate
IL180112A0 (en) Condensed benzamide compounds and pharmaceutical compositions containing the same
AU2003246810A1 (en) Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives
EP1745792A4 (en) Adsorbent for oral administration, preventive or remedy for kidney disease and preventive or remedy for liver disease
WO2006131591A3 (en) An entacapone-containing oral dosage form
HK1163672A1 (en) Processes for the preparation of compounds
WO2006056696A3 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
PT2033629E (en) Solid pharmaceutical composition comprising valsartan
EP1637167A3 (en) New injectable formulations containing progesterone
WO2005084648A8 (en) Pharmaceutical compositions comprising candesartan cilexetil
WO2006090268A3 (en) Processes for the preparation of alfuzosin and salts thereof and novel crystalline forms of alfuzosin
WO2005107717A3 (en) Oral dosage form for the extended release of biguanide and sulfonylurea
ZA200705131B (en) Solid pharmaceutical composition comprising valsartan
IL177735A0 (en) Combined pharmaceutical composition for the inhibition of the decline of cognitive functions
WO2006055663A3 (en) The use of novel antibacterial compounds
WO2006004613A3 (en) Guanylhydrazone salts, compositions, processes of making and methods of using
WO2006138431A3 (en) Methods and pharmaceutical formulations for increasing bioavailability
EP2325169A3 (en) Lisofylline analogues and their pharmeacuetical uses
EP1797074A4 (en) Compounds, compositions containing them, preparation thereof and uses thereof iiii
AU2003265373A1 (en) Preparation of aztreonam

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 46/2005 UNDER (71) DELETE "KESARWANI, AMIT, KUMAR [IN/IN]; HOUSE NO. 45, VIVEK VIHARCOLONY, JWALAPUR, HARIDWAR, SAHARANPUR 249 407, UTTAR PRADESH (IN)."; UNDER (72, 75) ADD "KESARWANI, AMIT, KUMAR [IN/IN]; HOUSE NO. 45, VIVEK VIHAR COLONY, JWALAPUR, HARIDWAR, SAHARANPUR 249 407, UTTAR PRADESH (IN)."

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase